Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for CareDx, Inc. (Nasdaq: CDNA), a precision medicine company focused on genomics‑based transplant diagnostics and related solutions. Through these filings, investors and analysts can review how CareDx reports its financial performance, governance changes, and other material events connected to its transplant‑focused business.
CareDx uses Form 8‑K to disclose current events such as quarterly financial results, preliminary annual results, leadership and board appointments, amendments to its bylaws, and information about shareholder derivative litigation settlements. For example, recent 8‑K filings describe revenue by category (testing services, product, and patient and digital solutions), changes in executive roles, adoption of a majority voting standard for director elections, and court approval milestones for a proposed settlement of shareholder litigation.
In addition to current reports, investors typically consult annual reports on Form 10‑K and quarterly reports on Form 10‑Q for more detailed discussions of CareDx’s transplant diagnostics business, segment information, and risk factors. These periodic reports complement the 8‑K disclosures by providing broader context on the company’s operations in non‑invasive molecular testing, lab products, and patient and digital solutions for transplant care.
On Stock Titan, CareDx filings are updated as they become available from EDGAR and are paired with AI‑powered summaries that highlight key points from lengthy documents. These summaries are designed to help readers quickly understand topics such as revenue composition, governance updates, compensation arrangements, and litigation‑related disclosures, while still allowing direct access to the original SEC filings for detailed review.
CDNA disclosed proposed sales of common stock via a Rule 144 notice. The submission lists 10,282 shares associated with restricted stock units dated 04/15/2025 and shows recent 10b5-1 sales by John Hanna of 19,280 and 200 shares on 01/22/2026 and 01/21/2026, respectively.
CareDx, Inc.'s President and CEO John Walter Hanna Jr. reported a routine tax-related share disposition. On the vesting of restricted stock units, 62,049 shares of common stock were withheld by the company at $17.57 per share to cover tax obligations. After this withholding, he continues to hold 686,757 common shares directly, indicating he retains a substantial equity position in the company.
CareDx, Inc. entered a definitive agreement to sell its Lab Products business, including Swedish subsidiary CareDx AB and related software assets, to Eurobio Scientific for $170 million in cash, subject to customary working capital and other adjustments.
The transaction is intended to sharpen CareDx’s focus on its core U.S.-based Precision Medicine Testing Services and Patient and Digital Solutions, simplify its operating model, and support AEBITDA margin expansion. Closing is subject to customary conditions, including Swedish regulatory review, and is targeted by the end of CareDx’s third quarter 2026.
CareDx expects to allocate proceeds using a disciplined capital approach, prioritizing growth investments aligned with its Precision Diagnostics Solutions model and potentially returning capital to shareholders. For the first quarter of 2026, the company reports preliminary testing services revenue growth of approximately 48% year over year, testing volume growth of about 17%, and Patient and Digital Solutions revenue growth of roughly 33%.
CareDx, Inc. Secretary and General Counsel Jeffrey Adam Novack reported a routine tax-related share disposition. On the vesting of restricted stock units, 1,892 shares of common stock were withheld by the company at an implied value of $17.82 per share to cover tax obligations.
After this withholding, Novack directly holds 119,485 shares of CareDx common stock, indicating he retains a substantial equity stake even after satisfying these tax liabilities.
CareDx, Inc. President and CEO Hanna John Walter JR reported a routine tax-related share withholding. On issuance of shares upon vesting of restricted stock units, 35,037 shares of common stock were withheld at $17.87 per share to satisfy tax withholding obligations. After this non‑market transaction, he directly holds 748,806 shares of CareDx common stock.
CareDx, Inc. executive Keith Kennedy, the company’s CFO and COO, reported a routine tax-related share withholding. On the vesting of restricted stock units, 11,725 shares of common stock were withheld by the issuer at $17.87 per share to cover tax obligations.
Following this tax-withholding disposition, Kennedy directly holds 197,414 shares of CareDx common stock. The transaction reflects compensation-related share settlement mechanics rather than an open-market purchase or sale.
CareDx, Inc. Chief Commercial Officer Jessica Meng reported a tax-related share disposition tied to vested restricted stock units. On the vesting of these RSUs, 7,386 shares of Common Stock were withheld by CareDx at $17.87 per share to cover tax withholding obligations.
After this non-market, tax-withholding transaction, Meng directly holds 169,392 shares of CareDx common stock. The event reflects routine share withholding for taxes rather than an open-market sale or purchase decision.
CareDx, Inc. reported that Secretary and General Counsel Jeffrey Adam Novack had 3,987 shares of common stock withheld on April 1, 2026 to cover tax obligations tied to the vesting of restricted stock units. These shares were retained by the company rather than sold in the market. After this tax-withholding transaction, he directly holds 121,377 shares of CareDx common stock.
Goldberg Michael reported acquisition or exercise transactions in this Form 4 filing.
CareDx, Inc. director Michael Goldberg received an automatic quarterly grant of 1,981 shares of common stock on 2026-04-02. The shares were granted at no cash cost in lieu of cash non-employee director compensation under the company’s Outside Director Compensation Policy. Following this award, he directly holds 185,942 common shares.
CareDx, Inc. director Michael Goldberg exercised stock options to acquire additional common shares. On March 31, 2026, he exercised options covering 26,500 shares of CareDx common stock at exercise prices of $5.02, $4.95, and $1.22 per share.
Following these option exercises, Goldberg directly owned 183,961 shares of CareDx common stock. The exercised options were originally subject to vesting schedules beginning in 2016 and 2017, with monthly vesting thereafter as described in the filing footnotes. No sales or gifts were reported in this filing.